BioSpace News Archive

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced that the company will report fourth quarter and full year 2020 financial results on March 24, 2021.

Efficacy was highest in patients over the age of 60, the population most vulnerable to severe complications and death with COVID-19 infection

XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that 4,286,438 warrants that were issued in connection with the February 2020 private placement and expired February 28, 2021 have been exercised for aggregate proceeds of $1,037,524.

Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care

Innoforce, a biopharmaceutical innovation enabling platform and PDMO, and dMed, a clinical CRO with strong presence in China and the US - the world’s two largest pharmaceutical and drug development markets, have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.

Presage Biosciences, Inc., a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology intratumoral microdosing platform, announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics.

Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference

Company will provide business updates during the earnings call and release investor day video segments on Company website

Science Applications International Corp. (NYSE: SAIC) is scheduled to issue its fourth quarter and full fiscal year 2021 results and hold a conference call after close of market on Thursday, March 25, 2021. SAIC executive management will discuss operational and financial results in a conference call beginning at 5:00 p.m. eastern time following issuance of the Company’s earnings press release.

Vedanta Biosciences , a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its executive team will present and host one-on-one meetings at the following virtual investor conferences: Chardan 3rd Annual Microbiome Medicines Summit Date: Monday, March 8, 2021